Timothy J Stuhlmiller Selected Research

Timothy J Stuhlmiller Research Topics

Disease

11	Neoplasms (Cancer) 05/2021 - 05/2013
2	Glioblastoma (Glioblastoma Multiforme) 04/2024 - 10/2017
2	Melanoma (Melanoma, Malignant) 01/2022 - 05/2014
2	Triple Negative Breast Neoplasms 01/2019 - 01/2017
2	Breast Neoplasms (Breast Cancer) 03/2018 - 04/2015
1	Brain Neoplasms (Brain Tumor) 04/2024
1	Disease Progression 04/2024
1	Glioma (Gliomas) 04/2024
1	Frontotemporal Dementia (Semantic Dementia) 01/2021
1	Tauopathies 01/2021
1	Neurilemmoma (Schwannoma) 01/2019
1	Meningioma (Meningiomas) 01/2018
1	Cardiotoxicity 10/2017
1	Lung Diseases (Lung Disease) 01/2017
1	Cystic Fibrosis (Mucoviscidosis) 01/2017

Drug/Important Bio-Agent (IBA)

8	Phosphotransferases (Kinase)IBA 01/2019 - 05/2014
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 05/2014
2	Transcription Factors (Transcription Factor)IBA 04/2024 - 05/2013
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022 - 05/2014
2	Lapatinib (GW572016)FDA Link 05/2021 - 04/2015
2	trametinibIBA 01/2017 - 05/2014
1	Biomarkers (Surrogate Marker)IBA 04/2024
1	MicroRNAs (MicroRNA)IBA 04/2024
1	ulixertinibIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 05/2021
1	pertuzumabIBA 05/2021
1	Adenosine Triphosphate (ATP)IBA 05/2021
1	Monoclonal AntibodiesIBA 05/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	tau Proteins (tau Protein)IBA 01/2021
1	1- (1- (3- (methylsulfonyl)phenyl)- 7- propoxyindolizin- 3- yl)ethanoneIBA 01/2019
1	Caspase 3 (Caspase-3)IBA 01/2019
1	CaspasesIBA 01/2019
1	OTX015IBA 01/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019
1	Neurofibromin 2 (Merlin)IBA 01/2019
1	Phenobarbital (Luminal)FDA Link 03/2018
1	ClaudinsIBA 03/2018
1	Sepharose (Agarose)IBA 03/2018
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	TOR Serine-Threonine KinasesIBA 01/2018
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2018
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	EphA1 Receptor (Eph Receptor)IBA 01/2018
1	Sorafenib (BAY 43-9006)FDA Link 10/2017
1	ErbB Receptors (EGF Receptor)IBA 10/2017
1	Sunitinib (Sutent)FDA Link 10/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2017
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2017
1	tyrosine receptor (receptor, tyrosine)IBA 01/2017
1	Epithelial Sodium ChannelsIBA 01/2017
1	dabrafenibIBA 05/2014
1	Oncogene Proteins (Oncogene Protein)IBA 05/2014
1	VemurafenibIBA 05/2014

Therapy/Procedure

5	Therapeutics 01/2022 - 10/2017